Clinical Trial Detail

NCT ID NCT03123939
Title Expanded Treatment Protocol in Acute Lymphoblastic Leukemia
Recruitment Active, not recruiting
Gender
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

childhood B-cell acute lymphoblastic leukemia

Therapies

Tisagenlecleucel

Age Groups: child adult

No variant requirements are available.